7 / 32
ROS1 rearrangement
•
Expressed in different tumours:
cholangiocarcinoma (8.7%), ovarian cancer (0.5%),
NSCLC (1-2%)
•
Whether the various ROS1 fusion kinases may have
different oncogenic properties is still unknown.
•
The resulting ROS1 fusion kinases present different
mechanism of activation, but all are constitutively
activated and lead to final cancer cell growth by
activation of downstream signaling pathways
•
Clinical and pathologic characteristics with a
significant overlap with ALK-positive patients:
•
young age (median age, 49.8 years),
never/light smokers, adenocarcinoma.
77% amino-acid identity within the ATP-binding sites